Trade Names:Accuretic- Tablets 10 mg quinapril/12.5 mg hydrochlorothiazide- Tablets 20 mg quinapril/12.5 mg hydrochlorothiazide- Tablets 20 mg quinapril/25 mg hydrochlorothiazide
Competitively inhibits angiotensin I-converting enzyme, resulting in the prevention of angiotensin I conversion to angiotensin II, a potent vasoconstrictor that stimulates aldosterone secretion. This action results in a decrease in sodium and fluid retention, an increase in diuresis, and a decrease in BP.Hydrochlorothiazide
Increases chloride, sodium, and water excretion by interfering with transport of sodium ions across renal tubular epithelium.
Treatment of hypertension.
Patients with a history of angioedema related to previous treatment with an ACE inhibitor; patients with anuria; hypersensitivity to sulfonamide-derived drugs or any component of the product.
The fixed combination is not indicated for initial therapy. The combination may be substituted for the titrated components.Adults
PO Quinapril monotherapy is an effective treatment of hypertension over a dose range of 10 to 80 mg/day administered every day. Hydrochlorothiazide is effective in doses of 12.5 to 50 mg every day. Patients whose BP is not adequately controlled with quinapril monotherapy may be given quinapril/hydrochlorothiazide (10/12.5 or 20/12.5). Further increases in dose of either or both components depend on the clinical response. Generally, the dose of hydrochlorothiazide should not be increased until 2 to 3 wk have elapsed.Renal Function ImpairmentAdults
No adjustment required as long as CrCl is greater than 30 mL/min; in severe renal function impairment, loop diuretics are preferred to thiazides.
Store tablets at controlled room temperature (68° to 77°F). Keep container tightly closed.
Electrolyte depletion may be intensified, especially hypokalemia.Alcohol, barbiturates (eg, phenobarbital), narcotics
Orthostatic hypotension may be potentiated.Anticoagulants (eg, warfarin)
Anticoagulant effect may be decreased.Antidiabetic agents (eg, insulin, sulfonylureas), antigout agents (eg, probenecid)
Dosage adjustment may be necessary because of possible hydrochlorothiazide-induced elevation in blood glucose levels.Cardiac glycosides (eg, digoxin)
Possible digitalis toxicity associated with hypokalemia.Cholestyramine, colestipol
May impair the absorption of hydrochlorothiazide.Insulin
In diabetic patients, requirements of insulin may be increased, decreased, or unchanged.Lithium
Plasma levels of lithium may be elevated, increasing the risk of toxicity.NSAIDs
May reduce the natriuretic and antihypertensive effect of hydrochlorothiazide.Potassium supplements, potassium-sparing diuretics (eg, spironolactone)
Increased risk of hyperkalemia.Nondepolarizing muscle relaxants (eg, tubocurarine)
Effects may be increased.Pressor amines (eg, norepinephrine)
Response to pressor amines may be decreased.Tetracycline and other drugs that interact with magnesium
Because of the magnesium content in quinapril, absorption of tetracycline may be reduced, decreasing the therapeutic effect.
May decrease serum protein-bound iodine levels without signs of thyroid disturbances.
Bradycardia; cor pulmonale; vasculitis; deep thrombosis; vasodilatation; chest pain.Quinapril
Dizziness; somnolence; paralysis; hemiplegia; speech disorder; abnormal gait; meningism; amnesia; headache; fatigue; insomnia; vertigo; asthenia.Quinapril
Lightheadedness; paresthesia; weakness; restlessness.
Urticaria; macropapular rash; petechiases.
Esophagitis; abnormal vision; rhinitis.Quinapril
Transient blurred vision; xanthopsia.
GI carcinoma; vomiting; diarrhea; nausea; abdominal pain; constipation; dyspepsia.Hydrochlorothiazide
Pancreatitis; sialadenitis; diarrhea; cramping; gastric irritation; anorexia.
Abnormal kidney function; albuminuria; pyuria; hematuria; nephrosis.Hydrochlorothiazide
Renal failure; renal function impairment; interstitial nephritis.
Aplastic anemia; agranulocytosis; leukopenia; thrombocytopenia; hemolytic anemia.
Cholestatic jaundice; hepatitis.Hydrochlorothiazide
Jaundice (intrahepatic cholestatic).
Hyperglycemia; glucosuria; hyperuricemia; hypokalemia; hyponatremia; hypochloremic alkalosis.
Coughing; pneumonia; asthma; respiratory infiltration; lung disorder; upper respiratory tract infection; bronchitis.
Shock; accidental injury; neoplasm; cellulitis; ascites; generalized edema; hernia; myopathy; myositis; arthritis; myalgia; viral infection; angioedema.Quinapril
Back pain; anaphylactoid reactions.Hydrochlorothiazide
Muscle spasm; hypersensitivity (including necrotizing angiitis, Stevens-Johnson syndrome, respiratory distress [including pneumonia and pulmonary edema], purpura, urticaria, rash, and photosensitivity).
When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, discontinue therapy as soon as possible.
Monitor blood sugar in diabetic patient when drug is started or dose is changed.
Category D (second and third trimester); Category C (first trimester). ACE inhibitors (eg, quinapril) can cause injury or death to fetus if used during second or third trimester. When pregnancy is detected, discontinue as soon as possible.
Excreted in breast milk.
Safety and efficacy not established.
Select dose with caution, reflecting greater frequency of decreased hepatic, renal, or cardiac function and comorbidity.
Use with caution.
Use with caution.
Reported in patients with a history of angioedema, undergoing desensitizing treatment with Hymenoptera venom, and in patients dialyzed with high-flux membranes.
Use with extreme caution in patients with a history of angioedema. Angioedema associated with laryngeal edema may be fatal. Angioedema may occur more frequently in black patients receiving an ACE inhibitor compared with non-black patients.
Chronic cough may occur during treatment.
Treatment with thiazide diuretics has been associated with hypokalemia, hyponatremia, hypochloremic alkalosis, hypercalcemia, and hypomagnesemia. Do not initiate therapy prior to correction of imbalance.
Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and death.
Decreases in BP may occur, especially in salt- or volume-depleted patients as a result of dialysis, prolonged diuretic therapy, dietary salt restriction, diarrhea, or vomiting. Volume and salt depletion should be corrected before initiating therapy with quinapril/hydrochlorothiazide.
Thiazide diuretics tend to reduce glucose tolerance, raise cholesterol, triglycerides, and uric acid levels.
Has occurred with other ACE inhibitors.
In patients undergoing surgery or during anesthesia with agents that produce hypotension, angiotensin II formation, secondary to compensatory renal release, may be blocked.
Hydrochlorothiazide may exacerbate or activate SLE.
Dehydration, electrolyte imbalance (hypokalemia [which may accentuate cardiac arrhythmias in patients receiving digitalis], hypochloremia, hyponatremia), hypotension.
Copyright © 2009 Wolters Kluwer Health.